title: Decline of Haemophilus influenzae type b disease in a region of high risk: impact of passive and active immunization.
abstract: Haemophilus influenzae type b (Hib) is a major cause of serious childhood bacterial infections. Before 1989 Alaska Native infants in the Yukon Kuskokwim Delta (YKD) had the highest recorded Hib disease rate, 2960:100,000 in children less than 1 year of age with 6 to 35 (mean, 13) cases/year between 1980 and 1988. In July, 1989, Alaska Area Native Health Service initiated a passive immunization project in the YKD using bacterial polysaccharide immunoglobulin (BPIG) administered at 3-month intervals to prevent Hib infections in infants less than 13 months of age. On January 1, 1991, after licensure of Hib conjugate vaccines for infants, the program was modified to a passive-active strategy using BPIG at birth and PedvaxHIB at 2, 4 and 12 months of age. Between July 1, 1989, and December 31, 1990, 80% of YKD children less than 1 year of age received at least 1 dose of BPIG. During this period there were 7 Hib cases in this age group, but only 1 of the cases had received any BPIG. Between January 1, 1991, and December 31, 1992, 4 Hib cases occurred in 2 YKD children. During the combined period, July 1, 1989, to December 31, 1992, the incidence of Hib disease for infants less than 1 year of age was 302:100,000. A dramatic decrease in Hib disease was observed in this high incidence region concurrent with implementation of passive and passive-active immunization strategies.
authors.affiliation: Alaska Area Native Health Service, Anchorage 99501.
authors.forename: R J
authors.initials: RJ
authors.lastname: Singleton
authors.forename: N M
authors.initials: NM
authors.lastname: Davidson
authors.forename: I J
authors.initials: IJ
authors.lastname: Desmet
authors.forename: J E
authors.initials: JE
authors.lastname: Berner
authors.forename: R B
authors.initials: RB
authors.lastname: Wainwright
authors.forename: L R
authors.initials: LR
authors.lastname: Bulkow
authors.forename: C M
authors.initials: CM
authors.lastname: Lilly
authors.forename: G R
authors.initials: GR
authors.lastname: Siber
mesh_terms: D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D004311:Double-Blind Method; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D007223:Infant; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000276:immunology
chemical_list: D001425:Bacterial Outer Membrane Proteins; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate